{"schema_version":"secwatch.filing_event.v1","accession":"0000875045-23-000012","form_type":"8-K","ticker":"BIIB","cik":"0000875045","company_name":"BIOGEN INC.","filed_at":"2023-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.512589+00:00","generated_at":"2026-06-16T17:53:13.175200+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Biogen posts Q1 GAAP EPS $2.67, non-GAAP $3.40; reaffirms FY23 guidance; multiple regulatory milestones","bullets":["Q1 revenue $2,463M (-3% YoY); GAAP EPS $2.67 (+30%); Non-GAAP EPS $3.40 (-6%).","LEQEMBI Alzheimer's drug: FDA Accelerated Approval, traditional filing Priority Review; PDUFA July 6, 2023.","Zuranolone depression NDA accepted with Priority Review; PDUFA Aug 5, 2023.","Tofersen SOD1-ALS PDUFA date April 25, 2023; Advisory Committee backed surrogate endpoint.","Appointed Chuck Triano (IR) and Adam Keeney (Corporate Dev); cost optimization program initiated."],"urls":{"canonical":"https://secwatch.observer/filing/0000875045-23-000012","json":"https://secwatch.observer/filing/0000875045-23-000012.json","markdown":"https://secwatch.observer/filing/0000875045-23-000012.md","text":"https://secwatch.observer/filing/0000875045-23-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875045/000087504523000012/0000875045-23-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875045/000087504523000012/biib-20230425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T17:53:13.175200+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d8db6e49eb39dedcd42b37504a4d24f77f9562be","claim":"BIOGEN INC. reported first quarter ended March 31, 2023 results: revenue $2,463 million, EPS $2.67. Guidance reaffirmed.","evidence_excerpt":"three potential launches in 2023; Company reports first quarter 2023 results and reaffirms full year 2023 guidance First quarter 2023 financial results • First quarter revenue $2,463 million; GAAP diluted EPS $2.67; Non-GAAP diluted EPS $3.40 Poised for leadership in Alzheimer’s disease (AD) with LEQEMBI and BIIB080 • LEQEMBI (lecanemab-irmb) FDA Accelerated","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875045/000087504523000012/0000875045-23-000012-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$2,463 million"},{"label":"EPS","value":"$2.67"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}